secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001689548-24-000035
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis: FY2023 net loss $123.3M; cash $247.6M; ulixacaltamide Phase 3 on track, PRAX-628 topline expected 1Q24
--------------------------------------------------------------------------------

- Cash and equivalents $247.6M as of Feb 29, 2024, funded by $161.7M January 2024 follow-on; runway into 2026.
- FY2023 net loss $123.3M vs $214.0M in 2022; R&D expenses fell to $86.8M from $155.0M.
- Essential3 Phase 3 program for ulixacaltamide (ET) has >3,000 pre-qualified referrals; enrollment due 1H24, topline 2H24.
- PRAX-628 PPR study 15 mg cohort exceeded expectations; topline data expected Q1 2024; Phase 2b plan in 2H24.
- Elsunersen (PRAX-222): 43% median seizure reduction in EMBRAVE Part 1; EMA PRIME designation for SCN2A DEE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000035/0001689548-24-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000035/prax-20240305.htm
  HTML page:      https://secwatch.observer/filing/0001689548-24-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer